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The characterization and isolation of various stem cell populations, from embryonic through tissue-derived stem cells, have led a
rapid growth in the field of stem cell research. These research efforts have often been interrelated as to the markers that identify
a select cell population are frequently analyzed to determine their expression in cells of distinct organs/tissues. In this review, we
will expand the current state of research involving select tissue-derived stem cell populations including the liver, central nervous
system, and cardiac tissues as examples of the success and challenges in this field of research. Lastly, the challenges of clinical
therapies will be discussed as it applies to these unique cell populations.
1. Introduction
Stem cells are broadly defined as cells capable of going
through numerous cycles of cell division, maintaining an
undifferentiated state and having the capacity to differentiate
into specialized cell types. They will often go through
asymmetric division where the stem cell creates a copy of
itself and a daughter cell that is capable of differentiation
[1]. Stem cells are further classified into three categories:
totipotent, pluripotent, or multipotent somatic. A totipotent
cell has the ability to form an entire organism (e.g., a
fertilized egg). Pluripotent stem cells lack the ability to form
extraembryonic tissue and are therefore unable to generate a
fetus. Examples of pluripotent cells include embryonic stem
cells which can give rise to any cell type from the three
germ cell layers (i.e., endoderm, mesoderm, or ectoderm).
Adult stem cells or mesenchymal stem cells (MSCs) are
examples of pluripotent stem cells that are isolated from
mature tissues and differentiate into other tissue types.
Multipotent somatic stem cells are capable of differentiating
into a variety of closely related cells within a tissue, but lack
the ability to differentiate into other tissues. A much studied
area of multipotent somatic stem cells is the hematopoietic
stem cell (HSC) which generates daughter cells that in turn
differentiate into all subpopulations of hematopoietic cells
(e.g., red blood cells, platelets, etc.) [2].
Several challenges persist when investigating individual
stem cell populations [3]. These hurdles include identifying
unique markers for the cells, ability to isolate the cells
and potential legal and ethical concerns around this field
of research. There are well-documented techniques on the
methods to obtain embryonic stem cells from the blastocyst
and grow them in culture [4]. Subsequent work has demon-
strated that these cells can be coaxed into a variety of different
cellular subtypes based upon their local environment [5–8].
Challenges in embryonic stem cell research have come from
both biologic and regulatory areas. The proliferative and
pluripotent nature of embryonic stem cells have been associ-
ated with the development of teratomas, an obvious problem
when designing clinical therapies [9]. From the regulatory
perspective, there were federal laws that previously limited
the use of certain embryonic stem cells; recent changes in the
law have relaxed these restrictions.
Identifying and isolating somatic stem cells from mature
organs is a greater challenge. Pluripotent cells are thought
to exist in most adult tissues, but their low frequency and
lack of identified unique cell surface markers make it difficult
to isolate these cells. Maintaining these stem cells in an
undifferentiated state or even directing their differentiation
requires understanding the signaling pathways that naturally
occur in the cells’ extracellular environment (e.g., the “stem
cell niche”). The local milieu provides critical signals for
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most stem cell populations to continue self-renewal [10].
Upon exiting the niche these cells begin to differentiate into
a committed cell [11–13]. Recent work involving stem cell
signaling pathways has enabled researchers to reprogram
somatic cells to exhibit essential characteristics of embryonic
stem cells [14–16]. This technique of harvesting accessible
somatic cells (e.g., hematopoietic cells or adipocytes) and
then inducing them into other tissue types is an active area
of investigation (i.e., induced pluripotent stem cells). Stem
cell differentiation into the functional phenotype of heart,
liver, pancreas, nervous system, and gut are under active
investigation. The following outline is a summary of research
in stem cell biology and its potential clinical applications
within select fields.
2. Pancreas
2.1. Anatomy and Function of Tissue. The human pancreas is
a glandular organ that serves both endocrine and exocrine
functions. The exocrine pancreas is comprised of acinar,
centroacinar, and duct cells. These cells manufacture and
secrete enzymes and alkaline fluids into the intestinal tract
to facilitate digestion. The endocrine pancreas consists of the
Islets of Langerhans which are mixed cell clusters that pro-
duce hormones for excretion into the blood stream. These
cell-type-specific hormones include insulin and glucagon
which are essential in glucose regulation. Other hormones
produced in the Islets of Langerhans include somatostatin
which is important in digestive regulation.
2.2. Clinical Need for Tissue Engineering. The pancreas has
been implicated in many disease states [17] and plays a
particularly important role in glucose regulation. Type 1
diabetes occurs secondary to multiple factors that lead
to a paucity of pancreatic β cells within the Islets of
Langerhans. This renders an individual unable to regulate
blood glucose levels without the use of exogenous insulin and
currently affects nearly 5 million individuals worldwide [18].
Pancreatic islet cell transplantation has been heralded as a
curative treatment for these patients [19, 20]. Unfortunately
the limited supply of pancreatic tissue for transplantation
and ongoing immunologic issues are two major hurdles that
have prevented broader success with this therapy [20].
2.3. Potential of Embryonic Stem Cells for Tissue. Embry-
ologic development of the pancreas has been closely stud-
ied and known mediators and transcription factors have
been identified in pancreatic development. Activin- and
(fibroblast growth factor-2) FGF-2 mediated repression of
sonic hedgehog expression have been implicated in pre-
pancreatic development from dorsal endoderm [17]. These
factors induce (pancreatic and duodenal homeobox 1) Pdx1
expression which is thought to be the master regulator
for further pancreatic development [17]. The subsequent
determination of insulin producing β cells occurs by sequen-
tial expression of the transcription factors Nkx2.2, Pax2,
NKx6.1, MafQ, Pax6, and Pdx1 [21]. Knowledge of this
pathway has allowed researchers to focus on developing
functional insulin-producing cells from pluripotent stem
cells by manipulating cell culture medium [6, 22].
Human embryonic stem cells have been successfully
cultured to create pancreatic islet cells that produce insulin
and C-peptide in response to glucose stimulation. Jiang
et al. describe a 36-day protocol that involves mixing
human embryonic stem cells (HESCs) in vitro with Pdx1,
Ptf1a/p48, Activin, and FGF in a sequential fashion to drive
differentiation into functional pancreatic cells [23]. In vitro
C-peptide levels were measured but in vivo functionality was
not studied. This protocol has been repeated among other
groups with slight variations in the cell culture medium
and transcription factors [24–27]. These efforts and other
cell culture manipulations have fueled the debate that
possible contaminants are leading to the impression of cell
differentiation.
2.4. Potential of Adult Stem Cells for Tissue. Identification
and isolation of a defined pancreatic stem cell capable of
giving rise to β cells has been somewhat controversial. There
has been an ongoing debate surrounding the presence of
a persistent stem cell subpopulation versus regeneration
through self-duplication of adult pancreatic betacells [21,
28–33]. Evidence suggests that a subpopulation of ductal
cells is capable of differentiation but the cell numbers are
small and obtaining these cells for functional investigation
has been difficult [18, 34]. Current initiatives are aimed at
identifying molecular markers that characterize pancreatic
stem cells and facilitate their isolation.
2.5. Clinical Studies. Some of the most advanced clinical
studies have come from the use of bone marrow-derived stem
cells. Karnieli et al. demonstrated that bone marrow stem
cells induced with Pdx1 and other factors can functionally
resemble pancreatic cells [25]. Bone marrow-derived cells
that have been induced with Pdx1 have been inserted under
the renal capsule in diabetic animals and treated animals
became normoglycemic after transplantation of manipulated
cells [35]. Similar results have been demonstrated in mice
after viral vector injection of manufactured insulin produc-
ing cells from bone-marrow stem cells [25].
Overall, the clinical need for appropriate therapies for the
treatment of type 1 diabetes is clear. The number of patients
that undergo pancreas or islet cell transplant remains limited
relative to the number of patients afflicted with this disease.
The breadth of efforts in stem cell research from embryonic
stem cells through adult pluripotent cells has been somewhat
successful in animal models. Translational efforts in clinical
trials will be the obvious critical step in the domain of
diabetes therapy.
3. Cardiac
3.1. Anatomy and Function of Tissue. The human heart is a
muscular organ that is responsible for pumping oxygenated
blood from the lungs to peripheral tissues. The cardiac
tissue is comprised of three layers. The innermost layer is
the endocardium which lines the inner chambers of the
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heart. Surrounding this is the myocardium which consists
of cardiac myocytes (i.e., involuntary striated muscle cells).
These cells contract in response to electrical stimuli. The
fibrous epicardium functions as a scaffold to provide shape
and form to the heart. Blood supply arrives to the cardiac
tissue through the coronary vessels.
3.2. Clinical Need. Heart disease is the number one cause
of mortality in the United States. A myocardial infarction
occurs secondary to a blockage in the coronary vessels
supplying the cardiac myocytes. Myocytes die in response
to the ischemic event thereby forming a scar in the tissue.
Surrounding the infracted area is a region of stunned or
“hibernating” myocardium. The likelihood of acutely dying
from a myocardial infarct has decreased 30% over the
past 20 years, because of improvements in management of
heart disease. However, the number of people living with
compromised heart function has nearly doubled over the
same period [36]. For patients with a new diagnosis of
congestive heart failure there is a mortality rate of 20%
within the first year and 50% within two years [37]. The
prevalence and pathophysiology of heart disease makes it a
principal target for novel therapies. Areas of investigation
include the role of stem cells in cardioprotection and/or
remodeling after myocardial infarction.
3.3. Potential of Embryonic Stem Cells for Tissue. Cardiac-
myocyte-like cells have been induced from embryonic stem
cells by coculture with endodermal feeder layers and/or
growth factors. These induced cell populations form con-
tractile tissue that expresses troponin and other markers
demonstrated in mature cardiac myocytes [38]. Embryonic
derived cardiac myocytes are currently being explored for
their therapeutic potential in injured myocardium [39].
3.4. Potential of Adult Stem Cells for Tissue. Studies of
heart transplant recipients demonstrate that host cells from
hematopoietic origins can repopulate the new myocardium
[40]. This has been used as evidence to support the idea that
bone marrow derived progenitor cells (BMCs) may provide
assistance to the injured heart. Cardiomyocyte progenitor
cells have also been identified within the epicardium of the
heart. These cells are thought to repopulate the heart in times
of injury and animal models have evaluated their therapeutic
efficacy after myocardial infarction [41, 42]. Bearzi et al.
identified a class of human c-kit-positive cardiac cells that
possess the fundamental properties of stem cells: they are
self-renewing, clonogenic, and multipotent. When these
cells were locally injected in the infarcted myocardium of
immunodeficient mice the human cardiac stem cells generate
a chimeric heart [41].
3.5. Clinical Studies. Large-scale studies to assess the effec-
tiveness of bone marrow stem cell implantation after myocar-
dial infarction include the Reinfusion of Enriched Progenitor
Cells and Infarct Remodeling in Acute Myocardial Infarction
(REPAIR-AMI) and Bone MarrOw Transfer to Enhance
ST-elevation infarct regeneration (BOOST) trials. In the
REPAIR-AMI trial, patients who experienced a myocardial
infarct were randomized to receive either intracoronary
infusion of bone marrow cells or placebo after traditional
revascularization procedures (e.g., stenting). The primary
measured outcomes were: left ventricular ejection fraction
(LVEF), recurrent MI, additional revascularization proce-
dures, heart failure, and death. LVEF improved over time
in both the BMC recipient group as well as the placebo
group but the improvement was significantly greater at four
months in the bone marrow transplant group (P = .01) [43].
Death, recurrence of MI, and hospitalization when examined
together were also lower in the BMC group after 1 year (P =
.006) [43]. Given the safety profile of this treatment and the
beneficial effects in patients with the most severely impaired
left ventricular function, large-scale studies are warranted
to examine the potential effects of this novel approach on
the risk of death and complications in patients with large
acute myocardial infarctions and depressed left ventricular
contractile function [43].
The BOOST trial, like the REPAIR-AMI trial, included
patients with an acute ST elevation myocardial infarction
who underwent percutaneous coronary intervention (PCI).
Patients were prospectively randomized to receive optimal
medical therapy or medical therapy plus bone marrow
cell transplant [44]. After 6 months, the authors observed
a 0.7% absolute improvement in ejection fraction of the
control group versus 6.7% improvement in the bone marrow
transplant group (P = .0026). However, the improvement in
LVEF was not sustained at 18 months [44].
Ongoing trials have investigated the delivery and timing
of stem cell infusions in relation to the cardiac event. While
the optimal time for transplantation has not been delineated
in a randomized trial current data suggests that the most
effective time of delivery may be between 5–8 days after the
ischemic event [45].
Studies involving embryonic-derived cardiac myocytes
have shown some functional success, but thus far have
been limited to animal models [39]. Min et al. describe
direct injection of embryonic derived cardiac myocytes into
areas of injured heart after surgically induced myocardial
infarction. At 32-week follow-up the mice who received
stem cell injections demonstrated improved left ventricular
function and overall survival when compared to the sham
group. By histology, the stem cell group had a higher density
of blood vessels surrounding the area of infarct suggesting
that stem cells may enhance neovascularization in injured
myocardium.
4. Liver
4.1. Anatomy and Function of Tissue. The human liver is the
body’s chief metabolic organ. It is comprised of several cell
types including hepatocytes, cholangiocytes, kupffer cells,
stellate cells and endothelial cells. Among its many functions
are the production of proteins, the regulation of blood
glucose levels, and enzymatic degradation of toxins within
the body.
4.2. Clinical Need for Tissue Engineering. Due to the liver’s
essential regulatory and synthetic functions, hepatic failure is
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a life threatening condition. Although hepatic regeneration
can occur via terminally differentiated hepatocytes, this
regenerative capacity remains insufficient in the majority
of disease states and a patient may subsequently require
liver transplantation. Due to the shortage of available organs
and the need for lifelong immunosuppression, ongoing
research is focused on strategies to repopulate the liver with
functioning hepatocytes through cell transplantation.
4.3. Potential of Embryonic Stem Cells for Tissue. Embryonic
stem cells serve as a potential source for cell transplantation
to reconstitute the diseased liver [46]. Studies utilizing
culture manipulation of embryonic stem cells have elicited
transformation into “hepatocyte-like cells” [46, 47]. A
challenge in working with pluripotent embryonic stem
cells is the potential for some cells to remain in the
undifferentiated state. When these undifferentiated cells are
transplanted there is the potential for unchecked growth
and teratoma formation. Current efforts aim to maximize
functional capacity and stability of induced hepatocytes for
transplantation [47, 48].
4.4. Potential of Adult Stem Cells for Tissue. Efforts to identify
a somatic-derived pluripotent cell within the liver have led to
the discovery of several multipotent cell types. Examples of
multipotent cells include the hepatoblast and oval cell. In the
fetal liver, hepatoblasts serve as precursors for hepatocytes
as well as cholangiocytes. These cells are characterized by
specific cell surface markers including alpha-fetoprotein
(AFP), EpCAM, and cytokeratins 17 and 19 [49]. During
embryogenesis, most of these cells terminally differentiate
into hepatocytes or biliary cells. However, a distinct cell
population maintains its capacity for self-renewal and dif-
ferentiation suggesting that hepatic stem cells persist in fetal
tissue [48].
In the adult liver, a bipotent progenitor cell capable of
forming both liver and biliary epithelium has been identified.
These cells, termed oval cells, reside in the terminal bile ducts
of the adult liver, and maintain a high nuclear/cytoplasmic
ratio [50–52]. They express markers of immature liver and
biliary epithelium including alpha-fetoprotein (AFP) and
CK19, respectively. Oval cells are found in increased number
after acute injury to the liver and are thought to play a role in
its regenerative capacity [51, 53, 54].
The adult derived hepatic progenitor cell is another
cell type found in the liver and localized to the “Canals
of Herring.” They appear distinct from the hepatoblast or
the oval cell as they are encountered without a preceding
injury to the tissue. Further investigations will need to be
performed to understand the overlap amongst the various
hepatic populations [55, 56].
4.5. Clinical Studies. Hepatocytes obtained from adult livers
have been used in clinical trials to treat liver disease ranging
from fulminant liver failure to inherited metabolic disorders
[57, 58]. Unfortunately the supply and viability of these cells
is limited [47]. Recent experimental studies involving adult-
derived hepatic progenitor cells or embryonic stem cells may
broaden the potential sources for cellular transplantation
[59–62].
Initial studies using embryonic stem cell-derived hep-
atocytes as well as induced pluripotent cells are under-
way in animal models. Kumashiro et al. demonstrated
improved liver function in mice with chemically induced
liver injury after transplantation with embryonic stem cell-
derived hepatocytes [47]. Similarly, induced pluripotent cells
including those of hematopoietic, adipogenic, and bone
marrow origins have been shown to improve hepatic fibrosis
in select animal models [63]. While some animal studies have
been initially successful, large-scale human trials involving
stem cells and liver failure have yet to be realized. Current
limits for these studies involve assuring stem cell stability and
a safe method for transplantation.
5. Nervous System
5.1. Anatomy and Function of Tissue. The nervous system,
a network of neurons and supporting cells that interpret
and respond to stimuli, is divided into two compartments.
The central nervous system (CNS) is comprised of the
brain and spinal cord. Oligodendrocytes are cells that create
the myelin sheath that surround the neurons of the CNS.
Myelination protects the neurons and aids in the speed of
signal transmission. The peripheral nervous system (PNS)
supplies sensory and motor information to and from the
extremities. Schwann cells myelinate the nerves of the
peripheral nervous system.
5.2. Clinical Need for Tissue Engineering. While peripheral
nerves have some regenerative capacity, damage to the
central nervous system usually results in permanent disabil-
ity. Therefore, degenerative conditions such as Parkinson’s
disease and multiple sclerosis are devastating diagnoses.
Similarly, traumatic spinal cord injury usually results in
irreversible paralysis. Treatment for these conditions has
traditionally been limited to supportive therapy. Recent
investigations have demonstrated a population of pluripo-
tent cells within the CNS that is responsible for repair
and regeneration. Recent efforts have been directed towards
harnessing the potential of these cells for therapeutic use.
5.3. Potential of Embryonic Stem Cells for Tissue. Embryonic
stem cells can be induced to form neurons and other
functional neural tissue. Ben-Hur et al. demonstrated that
functional neuronal cells could be derived from primate
embryonic stem cells using a stromal feeder coculture
system for neural induction with sequential exposure to
inductive signals, such as sonic hedgehog (SHH) and FGF-
8. This approach controls dopaminergic specification dur-
ing embryogenesis. After transplantation into immunosup-
pressed rats these cells maintain functional stability for 12
weeks [64]. In a primate model of Parkinson’s disease Takagi
et al. demonstrates stability of embryonic derived dopa-
manergic cells [65]. Other investigators have created and
transplanted embryonic derived Oligodendrocyte Progenitor
Cells (OPCs). Mice with spinal cord injuries demonstrated
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increased remyelination and improved locomotion after
injection of embryonic derived OPCs into the injury site
[66]. With these previous experimental studies, multiple
sclerosis and other demyelinating diseases are being evalu-
ated as therapeutic targets for OPCs.
5.4. Potential of Adult Stem Cells. During development,
the brain arises from a layer of neuroepithelial stem cells
that surrounds the lumen of the early neural tube. Recent
investigation has demonstrated that multipotent neural stem
cells continue to line the cerebral ventricles of the forebrain
in the adult brain. These cells have been isolated and
grown in culture. When transplanted into neural tissue, the
multipotent neural stem cells differentiate into neurons and
supportive neural tissue including oligodendrocytes and glial
cells [67].
5.5. Clinical Studies. Clinical applications of embryonic and
somatic derived neural stem cells are under investigation
for treatment of diseases that were once thought to be
irreversible (e.g., Parkinson’s disease, multiple sclerosis and
traumatic spinal cord injury). The following is a contempo-
rary description of progress in this field.
Parkinson’s disease results from destruction of nigros-
triatal dopamine containing neurons and physiologically
manifests as rigidity, bradykinesia, tremor, and postural
instability. Medical therapies to increase dopaminergic func-
tion have limited efficacy due to side effects and durability
of the treatment. Promising results using stem cell based
therapies have been reported by a number of groups
using preclinical models, but clinical safety and the long
term outcomes have not been demonstrated [68]. In one
study, Takagi et al. demonstrated an effective method to
create dopaminergic cells from embryonic stem cells. They
subsequently demonstrated stability of grafted cells as well
as functional improvement in motor behavior in a primate
model of Parkinson’s disease [65].
Current therapeutic efforts for spinal cord injuries are
directed at limiting progression of disease rather than
repairing the existing damage. Isolation of neural progen-
itor cells from adult or embryonic tissue may represent
a novel therapeutic approach [67]. In 2005, embryonic-
derived Oligodendrocyte Progenitor Cells (OPCs) were
transplanted into mice with spinal cord injuries. The mice
that received treatment demonstrated increased remyeli-
nation and improved locomotion [66]. Multiple sclerosis
and other demyelinating diseases are also being studied as
therapeutic targets for OPCs.
A limitation of stem cell transplantation of neural tissue
involves the low level of integration and stability of the
derived cells. Therefore, transplantation of a viable number
of these cells leading to durable functioning grafts will need
to be addressed for the initiation of clinical trials.
6. Cell Survival
In all of the described research areas, one of the crucial
elements involves understanding the processes that enable
stem cells to regenerate or differentiate. In adult tissue there
are relatively few stem cells within a given organ. Harnessing
the ability to expand these cells and maintain their undif-
ferentiated state is important before large scale therapeutics
can be realized. Purifying the cells and preventing teratoma
formation is paramount to ensure the safety of stem cell ther-
apies. Initial work with the forkhead 0 (fox0) family of tran-
scription factors suggests that these factors may be involved
in cell cycle arrest, differentiation, and apoptosis [69].
Further investigations to understand these mechanisms are
essential before the full potential of stem cells can be realized.
7. Conclusion
The field of stem cell research continues to expand with
characterization and isolation of various stem cell pop-
ulations from the embryonic stem cell to tissue-derived
cell populations. The clinical applications of embryonic
stem cells are limited by ethical concerns and the potential
of teratoma formation. Pluripotent cells which persist in
mature organs are also targeted for cellular transplantation
or organ regeneration. Recent gains in the understanding of
the stem cell niche and the signaling pathways which drive
stem cell differentiation have enabled investigators to induce
readily available cells such as adipocyte and hematopoietic
derived cells into other tissue types.
In this review we discussed four organ systems, the
pancreas, liver, heart, and neural systems. These were
selected due to the magnitude of their disease burden on
society. However, it should be recognized that stem cells
are also under clinical investigation in the fields of plastic
and reconstructive surgery [70], ophthalmology [71], and
hematopoietic diseases.
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